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ABSTRACT
Erectile dysfunction (ED) is a complication of diabetes, condition responsible for causing endothelial dysfunction (EDys) and hampering repair
mechanisms. However, scarce information is available linking vasculogenesis mediated by Endothelial Progenitor Cells (EPCs) and diabetes-
associated ED. Furthermore, it remains to be elucidated if glycemic control plays a role on EPCs functions, EPCs modulators, and penile vascular
health.Weevaluated theeffectsofdiabetes and insulin therapyonbonemarrow (BM)andcirculatingEPCs, testosterone, andsystemic/penileStromal
DerivedFactor-1 alpha (SDF-1a) expression.MaleWistar ratswere divided into groups: age-matched controls, 8-weeks streptozotocin-induced type
1 diabetics, and insulin-treated 8-weeks diabetics. EPCs were identiﬁed by ﬂow cytometry for CD34/CD133/VEGFR2/CXCR4 antigens. Systemic
SDF-1a and testosterone levels were evaluated by ELISA. Penile SDF-1a protein expression was assessed, in experimental and human diabetic
cavernosal samples, by immunohistochemical techniques. Diabetic animals presented a reduction of BM-derived EPCs and an increase in putative
circulating endothelial cells (CECs) sloughed from vessels wall. These alterations were rescued by insulin therapy. In addition, glycemic control
promoted an increase in systemic testosterone and SDF-1a levels, which were signiﬁcantly decreased in animals with diabetes. SDF-1a protein
expression was reduced in experimental and human cavernosal diabetic samples, an effect prevented by insulin in treated animals. Insulin
administration rescued the effects of diabetes on BM function, CECs levels, testosterone, and plasmatic/penile SDF-1a protein expression. This
emphasizes the importance of glycemic control in the prevention of diabetes-induced systemic and penile EDys, by the amelioration of endothelial
damage, and increase in protective pathways. J. Cell. Biochem. 118: 82–91, 2017. © 2016 Wiley Periodicals, Inc.
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E rectile dysfunction (ED) is a common complication of diabetes,having a profound negative impact on the quality of life of
men and their partners [Bortolotti et al., 1997]. In diabetic men, ED
occurs at an earlier age than the general population, increasing with
disease duration [Maiorino et al., 2014]. Diabetes-associated ED is a
multifactorial disorder, in which hyperglycemia and increased
oxidative stress induce changes in central nervous system,
peripheral nerve activity, and endothelial cell dysfunction (EDys)
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[Saenz de Tejada et al., 2005; Musicki and Burnett, 2007; Costa,
2012]. EDys comprises a number of functional alterations in the
endothelial monolayer, impairing vasorelaxation mechanisms, and
blood ﬂow perfusion, leading to ED and systemic vascular disease
[Musicki and Burnett, 2007]. Cavernosal EDys is recognized as a key
factor in diabetic-ED pathogenesis, where signiﬁcant endothelial
injuries may ultimately culminate in apoptosis, disrupting cav-
ernosal tissue homeostasis [Costa and Virag, 2009; Costa et al., 2009;
Costa, 2012]. In order to regenerate endothelial lesions, endogenous
vascular repair mechanisms of angiogenesis [Folkman and Shing,
1992] and vasculogenesis [Asahara et al., 1999] are usually
activated. However, it was reported that besides causing endothelial
damage, diabetes may also deleteriously affect re-endothelialization
events, exacerbating vasculopathy [Martin et al., 2003; Loomans
et al., 2004]. It was demonstrated that due to diabetes, several
angiogenic molecules and pathways are altered in penile tissue,
which may impair angiogenesis, and endothelial repair [Musicki and
Burnett, 2007; Castela et al., 2012]. However, the role of vasculo-
genesis, mediated by Endothelial Progenitor Cells (EPCs), in the
pathophysiology of diabetic-ED remains unknown. EPCs reside
within the bone marrow (BM), and are mobilized to the peripheral
circulation and recruited to vascular insult sites, where they
differentiate into mature ECs, integrating, and repairing damaged
vasculature [Asahara et al., 1999]. These processes are regulated
by many factors, including Stromal cell-Derived Factor-1
alpha (SDF-1a), which by binding CXCR-4 [Tzeng et al., 2011;
Suarez-Alvarez et al., 2012], play a relevant role in BM homeostasis,
and progenitor cells (PCs) trafﬁcking [Urbich and Dimmeler,
2004] and androgens, which may modulate EPCs functions [Foresta
et al., 2008; Castela et al., 2011]. Furthermore, it has been suggested
that a good glycemic control, besides improving endothelial
function and reducing oxidative markers [Fadini et al., 2011], and
may also increase circulating EPCs (cEPCs) [Hortenhuber et al.,
2013]. Several reports demonstrated a decrease in cEPCs levels in ED
patients with cardiovascular risk factors, including diabetes [Murata
et al., 2012; Maiorino et al., 2015]. A recent study, has showed a
reduction of cEPCs in type 1 diabetics (T1D) with ED, which
correlated with EDys and testosterone levels [Maiorino et al., 2015].
However, these publications have only investigated systemic EPCs
levels and their potential association with endothelial, and ED
parameters. In addition, the role of glycemic control on EPCs
functions and its effects on EPCsmodulators has never been assessed
in diabetes-associated ED. We aimed to study in an ED-prone
experimental model of diabetes [Jin et al., 2009; Castela et al., 2012],
the role of insulin therapy on EPCs production/mobilization, on
testosterone levels, and its impact in the systemic and penile
expression of SDF-1a.
MATERIALS AND METHODS
EXPERIMENTAL MODEL OF TYPE 1 DIABETES
Procedures described in this studywere performed in accordancewith
the ethical guidelines proposed by the Portuguese General Veterinary
Directorate (DGV) in theDirective of 24November 1986 (86/609/EEC),
with the recommendations of 18 June 2007 (2007/526/EC) proposed
by the Council of the European Communities. Male Wistar rats
(280–350g; Charles River Laboratories, Barcelona, Spain) were
maintained in a 12-h day–light cycle with free access to food, and
tap water. A total of 30 rats were randomly assigned to the following
groups (n¼ 10): age-matched healthy controls, 8-weeks diabetics,
and 8-weeks diabetics treated daily with insulin. T1D was induced by
streptozotocin, as described [Castela et al., 2012]. Immediately after
the onset of diabetes, a group of animals initiated a subcutaneous
treatment with 2U of insulin (Humulin NPH 100UI/ml, Lilly), twice a
day, for 8 weeks. Glucose levels were monitored before every insulin
administration to ensure normalization. To avoid the possible
inﬂuence of circadian regulation of EPCs production/trafﬁcking, at
the 8-week time point all animals were sacriﬁced at 9am [Thomas
et al., 2008]. Femurs and tibias were harvested, and blood samples
collected for EPCs characterization. Plasma was stored at 80°C,
penises excised andprocessed forOCT (OptimalCuttingTemperature)-
embedding, and immunohistochemistry.
HUMAN SAMPLES
All patients gavewritten informedconsent for the removal of cavernous
tissue, and this study was approved by the local ethics committee
according to the World Medical Association Declaration of Helsinki. A
total of 22 individuals were enrolled in this study. Eight men without
diabetes and without ED [(mean age standard error (SE); 32.1 3.6)],
one had a penile curvature correction, and the remaining had
procedures for penile enlargement and/or lengthening. Fourteen
patients with diabetes and ED (mean age SE; 61.5 2.1): 4 with
T1D and 10 with T2D, had penile implant surgery. During surgical
interventions, cavernosal fragments with 5–7.5mm length/2.5mm
width were harvested, and ﬁxed in formaldehyde. Corpus cavernosum
(CC) was processed for parafﬁn inclusion and immunohistochemistry
[Costa et al., 2009].
EPCs EVALUATION BY FLOW CYTOMETRY
BM and peripheral blood (PB)-isolated EPCs were characterized by
ﬂow cytometry for the expression of CD34, CD133, VEGFR2, and
CXCR4 antigens. These are the most consensual speciﬁc surface
markers currently used to characterize EPCs, which include antigens
that deﬁne the hematopoietic lineage, CD34 and CD133, in
combination with a marker of endothelial commitment, VEGFR2
[Peichev et al., 2000], and an EPCs mobilization antigen, CXCR4.
Combination of these antigens allowed the investigation of several
subpopulations displaying vasculogenic properties: CD34þ,
CD34þCD133þ, CD34þCD133þVEGFR2þ, CD34þCD133þCXCR4þ,
and CD34þCD133þVEGFR2þCXCR4þ. Markers of vascular
damage were also assessed in PB, through the characterization of
putative circulating endothelial cells (CECs) identiﬁed by
CD34þCD133-VEGFR2þ. Brieﬂy, total mononuclear cells (MNCs)
were isolated fromBMbyﬂushing femurs and tibias with phosphate-
buffered saline (PBS). PB MNCs were separated by Histopaque-1077
(Sigma–Aldrich, St. Louis, MO) density gradient centrifugation.
Approximately 3–5 millions BM and PB MNCs were stained during
30min at 4°C with the following rabbit anti-rat antibodies:
PE-anti-CD34 (1:50; Antibodies-online Inc., Atlanta, GA), Cy5.
5- anti-CD133 (1:10; Bioss Inc.,Woburn,MA), Alexa Fluor 488-anti-
VEGFR2 (1:10; Antibodies-online Inc.), and PE-Cy7- anti-CXCR4
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(1:20; Bioss Inc.). A Fixable Viability Dye eFluor
1
450 (eBioscience,
San Diego, CA) was added to all samples. An isotypematched control
was evaluated to achieve the appropriate settings. Results were
collected in a FACSanto II ﬂow cytometer (BD Biosciences, Franklin
Lakes, NJ) (1–2 million events) and analyzed using FlowJo software
(Ashland, OR).
SYSTEMIC QUANTIFICATION OF SDF-1a AND TESTOSTERONE
Plasma SDF-1a and testosterone levels were measured by ELISA.
Systemic SDF-1a was quantiﬁed using the Human CXCL12/SDF-1a
Immunoassay (R&D Systems, Abingdon, UK) and circulatory testoster-
one with the Testosterone Assay (R&D Systems), according to the
manufacturer0s protocol. Quantiﬁcation was performed at 450 and
550nm using a plate reader (Thermo Electron, Multiskan Ascent).
SDF-1a QUANTITATIVE IMMUNOHISTOCHEMISTRY
SDF-1a immunohistochemical detection was performed in experi-
mental and human CC, using the streptavidin-biotin-peroxidase
method [Costa et al., 2009]. Brieﬂy, sections were incubated
overnight with a cross-reactive rabbit anti-human SDF-1a
(1:1000; Abcam, Cambridge, UK), followed by the biotinylated
secondary antibody (Santa Cruz Biotechnology, CA) and the Avidin-
Biotin Complex reagents (Vector Laboratories, CA). Omission of the
primary antibody was used as negative control. Sections were
developed with diaminobenzidine (DAB; Sigma–Aldrich) and
counterstained with hematoxylin. Slides were visualized under the
Olympus AH3-RFCA microscope and images captured using the
Olympus C-35AD-4 camera (Olympus Imaging Europa GmbH,
Hamburg, Germany). Signal intensity was quantiﬁed using ImageJ
color deconvolution (v.1.37a, NIH, MD), as described [Castela et al.,
2012]. Brieﬂy, a DAB threshold value of 25 (rat) and 75 (human) was
selected for SDF-1a staining, by measuring the lowest and the
highest mean optical density values in 10 random DAB-positive
images. For each image, the sum of the intensity values in the regions
of interest (ROI), pixels above the brown threshold, was divided by
the ROI total area, producing an average unitless intensity value for
SDF-1a staining. All intensity values within the same group were
averaged to calculate an overall value, a relative measurement of
SDF-1a levels.
DUAL IMMUNODETECTION OF SDF-1a/a-SMOOTH MUSCLE ACTIN
(a-SMA)
To identify cavernosal cellular components expressing SDF-1a, a
double immunoﬂuorescence for SDF-1a/a-SMA was performed
[Costa et al., 2009]. Brieﬂy, rat and human sections were incubated
with the following antibodies: rabbit anti-SDF-1a (1:1000; Abcam)
and mouse anti-human a-SMA (1:500; Chemicon International,
Temecula, UK). Slides were incubated with the respective secondary
antibodies: donkey anti-rabbit conjugated with a red ﬂuorochrome
(1:1000; AlexaTM 568, Invitrogen, CA) and donkey anti-mouse
conjugated with a green ﬂuorochrome (dilution 1:1000; AlexaTM
488, Invitrogen). Primary antibodies were omitted in negative
controls. Nuclei were counterstained with DAPI (40,6-diamidino-
2-phenylindole; Invitrogen), slides were observed under the
ﬂuorescence microscope (Imager.Z1, Zeiss, Germany) and images
captured (Carl Zeiss MicroImaging GmbH, Germany).
STATISTICAL ANALYSIS
Statistical analyses were performed using the GraphPad Prism
software (GraphPad Software version 5.0, San Diego, CA). Data are
presented as mean SE. In studies with experimental rat model,
signiﬁcant differences between control, diabetes, and diabetesþ
insulin groups were determined by the One-way Analysis of
Variance (ANOVA), followed by the Bonferroni test. Signiﬁcant
alterations in quantitative immunostaining between human non-
diabetic, non-ED, and diabetic with ED groups were calculated using
Student0s t-test. A P value less than 0.05 was considered statistically
signiﬁcant.
RESULTS
EVALUATION OF BM-EPCs IN DIABETIC AND INSULIN-TREATED
ANIMALS
EPCs subsets were assessed by ﬂow cytometry by the surface
expression of CD34/CD133/VEGFR2/CXCR4 antigens. Figure
1A illustrates the ﬂow cytometry gating strategy used to identify
EPCs populations. Hematopoietic PCs were selected on the basis of
forward and side scatter values excluding the debris, aggregates, and
dead cells. The percentages and numbers of the distinct EPCs
subtypes were performed, based on the double or triple expression
of CD133, VEGFR2, and CXCR4 on CD34þ gated cells (G4).
Quadruple positive cells were quantiﬁed by analyzing the CD133
positivity on CD34þVEGFR2þCXCR4þ cells (G5). Data revealed that
hematopoietic stem/progenitor cells characterized by CD34þ and
CD34þCD133þmarkers were decreased in diabetics when compared
with controls and insulin-treated rats (Fig. 1B and C). Insulin
administration signiﬁcantly prevented diabetes effects on these
populations, as displayed in Figure 1B (diabetes: 0.68 0.05% vs.
diabetesþ insulin: 1.19 0.15%; P< 0.05) and Figure 1C (diabetes:
0.24 0.02% vs. diabetesþ insulin: 0.59 0.06%; P< 0.01).
In diabetic animals, the subpopulation expressing CD34þCD133þ
in conjunction with the VEGFR2 was also signiﬁcantly reduced in
comparison to controls (diabetes: 0.24 0.02% vs. controls:
0.54 0.09%; P< 0.01), and to insulin-administrated animals
(0.66 0.07%; P< 0.001) (Fig. 1D). Similar results were obtained
for cells co-expressing CD34þCD133þ and CXCR4þ, the chemokine
receptor for SDF-1a (Fig. 1E). In diabetics the percentage of cells
expressing these markers was decreased (0.19 0.02%), when
compared to non-diabetics (0.48 0.14%) and to insulin-
supplemented animals (0.51 0.08%; P< 0.001). The subpopulation
quadruple positive for CD34þCD133þVEGFR2þCXCR4þ was signif-
icantly decreased in the diabetic BM (0.12 0.04%) in comparison
to control (0.43 0.07%; P< 0.01), and insulin-treated rats
(0.39 0.06%; P< 0.001). Importantly, treatment with insulin
allowed to maintain all these cell populations to values in the range
of controls (Fig. 1F).
cEPCs LEVELS IN ANIMALS WITH DIABETES—EFFECTS OF INSULIN
ADMINISTRATION
cEPCs were identiﬁed as previously described for BM. Figure
2A shows the gating strategy used to evaluate EPCs in PB. Flow
cytometry was used to analyze cEPCs expressing the same
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combination of antigens, as for BM. Interestingly, when comparing
diabetic animals to controls and insulin-treated, we did not
observe signiﬁcant differences in the percentage of CD34þ,
CD34þCD133þ, CD34þCD133þVEGFR2þ, CD34þCD133þCXCR4þ,
and CD34þCD133þVEGFR2þCXCR4þ cells (Fig. 2B–F). However,
we have identiﬁed two cell populations, CD34þVEGFR2þ and
CD34þCD133-VEGFR2þ, increased in animals with diabetes
(Fig. 2G and H). The percentage of double positive CD34þVEGFR2þ
cells in diabetic rats (0.86 0.47%), was augmented as compared
to the non-diabetes group (0.57 0.29%) and with insulin-
administered animals (0.28 0.09%; P< 0.05) (Fig. 2G). CD34
and VEGFR2 are surface markers present in both EPCs and in mature
ECs, yet, the latter is negative for CD133. Our results demonstrated
an increase in CD34þCD133VEGFR2þ cells in diabetics
(0.79 0.13%), in comparison to controls (0.39 0.07%; P< 0.05)
and to insulin-treated rats (0.22 0.06%; P< 0.001) (Fig. 2H).
Fig. 1. Flow cytometry quantiﬁcation of bone marrow (BM) stem and endothelial progenitor cells (EPCs). (A) Representative ﬂow cytometry gating strategy used to analyze
BM-derived stem/vascular progenitor cells: exclusion of debris and aggregates, gating of live cells. Subsequently, cells expressing CD34 were gated and among those,
subpopulations identiﬁed by CD133, CXCR4, and VEGFR2. (B) Diabetic BM presented a decrease in CD34þ cells and a reduction in subpopulations of EPCs identiﬁed by the
following immunophenotypes: (C) CD34þCD133þ, (D) CD34þCD133þVEGFR2þ, (E) CD34þCD133þCXCR4þ, (F) CD34þCD133þVEGFR2þCXCR4þ. These alterations were
prevented by insulin administration. Data are expressed as Mean SE. P< 0.01, diabetic group compared with control group; #P< 0.05, ##P< 0.01, ###P< 0.001, diabetic
group compared with insulin-treated diabetics.
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Fig. 2. Flow cytometry quantiﬁcation of peripheral blood cells. (A) Representative ﬂow cytometry gating strategy of putative circulating endothelial cells (CECs): exclusion of
debris and aggregates, gating of live cells. Subsequently, cells expressing CD34 were gated and among those, subpopulations identiﬁed by VEGFR2 positivity and CD133. (B–F)
Percentage of CD34þ, CD34þCD133þ, CD34þCD133þVEGFR2þ, CD34þCD133þCXCR4þ, and CD34þCD133þVEGFR2þCXCR4þ cells, no signiﬁcant difference was observedwhen
comparing diabetic animals to controls and insulin-treated diabetics. (G and H) In the diabetic group a signiﬁcant increase was observed in subsets of cells characterized by (G)
CD34þVEGFR2þ, (H) CD34þVEGRF2þCD133, which may identify matured ECs sloughed from vascular walls. This effect was rescued to control levels, by insulin therapy. Data
presented as Mean SE. P< 0.05, diabetic group compared with control group; #P< 0.05, ###P< 0.001; diabetic group compared with insulin-treated diabetics.
JOURNAL OF CELLULAR BIOCHEMISTRY86 VASCULOGENESIS AND DIABETIC-ED
SDF-1a AND TESTOSTERONE LEVELS
Systemic SDF-1a and testosterone were evaluated by ELISA. As
shown on Figure 3A, animals with diabetes had a signiﬁcant decrease
in SDF-1a (982.60 72.46 pg/ml), as compared to controls
(1704.00 180.30 pg/ml; P< 0.001) and to insulin-treated rats
(1402.00 82.26 pg/ml; P< 0.01). Similarly, plasma testosterone
was reduced in diabetics (0.90 0.11 ng/ml), and rescued to control
values (2.09 0.41 ng/ml) by insulin supplementation
(2.23 0.1 ng/ml; P< 0.01) (Fig. 3B).
SDF-1a EXPRESSION IN RAT PENILE TISSUE
We evaluated if diabetes and insulin treatment had a role in cavernosal
SDF-1a expression, as quantiﬁed inDAB-labeled sections [Castela et al.,
2012]. Additionally, we identiﬁed CC components expressing SDF-1a,
by dual immunoﬂuorescence for SDF-1a/a-SMA. We observed
that SDF-1a (Fig. 4A) was signiﬁcantly decreased in diabetic CC
(62.34 3.23; P< 0.05) in comparison with controls (75.35 2.60), an
effect prevented by insulin administration (74.92 2.22) (Fig. 4A).
Dual immunoﬂuorescence revealed that SDF-1a was predominantly
detected in perivascular smooth muscle cells (SMCs) (Fig. 4C),
with some expression also perceived in endothelium of control and
insulin-administered animals (Fig. 4C, arrow head).
SDF-1a IMMUNOLABELING IN HUMAN CC
To verify if alterations in diabetic cavernosal SDF-1a expression were
not speciﬁc of rat, we performed analogous experiments in human
non-diabetes, non-ED, and indiabeteswithEDsamples. Consistentwith
the results obtained in experimental CC, human diabetic-ED penis
displayed a signiﬁcant decrease in SDF-1a protein (mean intensity
values 105.40 3.22 in non-diabetes, non-ED vs. 96.01 0.82 in
diabetes with ED samples; P< 0.01) as quantiﬁed in SDF-1a/DAB-
stained slides (Fig. 5A and B). SDF-1a/a-SMA immuno-colocalization
revealed that SDF-1a was predominantly present in SMCs of both
human non-diabetic and diabetic fragments (Fig. 5C).
DISCUSSION
In this study, we evaluated in a T1D experimental model the effects
of insulin treatment in EPCs functions, on testosterone levels, and in
the systemic and penile expression of SDF-1a. The main ﬁndings
suggested that insulin administration rescued diabetes effects in
endothelial damage and improved systemic, and cavernosal protec-
tive proteins/pathways involved in EPCs function/modulation,
highlighting relevance of glycemic control in preventing endothelial
dysfunction associated to diabetes.
We startedby evaluatingBMandperipheral EPCsbyﬂowcytometry,
analyzing ﬁve subpopulations identiﬁed by the following immuno-
phenotypes: CD34þ, CD34þCD133þ, CD34þCD133þVEGFR2þ,
CD34þCD133þCXCR4þ, and CD34þCD133þVEGFR2þCXCR4þ. All
subsets may comprise cells with vasculogenic capabilities, although
triple and quadruple antigen positive subpopulations, are considered as
bonaﬁde EPCs [Peichev et al., 2000]. We observed a decrease in all
immunophenotypes indiabeticBM,as compared to control and insulin-
treated. In agreement, previous studies also demonstrated a reduction in
BM-derived EPCs in experimental models of diabetes [Mohler 3rd et al.,
2009; Saito et al., 2012]. It was also reported that diabetes may be
responsible for BMmicroenvironment alterations [Oikawa et al., 2010;
Hazra et al., 2013; Westerweel et al., 2013] impairing stem, and PCs
production. Interestingly, this effect was prevented by insulin, which
seemed to restore BM functionality. These results, corroborated data
from a single publication demonstrating in a mouse model of diabetes
the beneﬁcial effects of insulin administration on BM cell production
[Saito et al., 2012].
Next, we investigated if diabetes and insulin therapy played a role
in cell trafﬁcking to PB. We did not observe signiﬁcant alterations,
between the three groups, in any of the analyzed EPCs subpopu-
lations. In fact, contradictory ﬁndings have been reported in what
regards cEPCs in diabetes. Several studies have presented a decrease
in vascular progenitors in diabetic PB [Murata et al., 2012; Saito
et al., 2012; Westerweel et al., 2013; Maiorino et al., 2015], whereas,
others have shown an increase in these cell populations [Fadini et al.,
2006; Liu et al., 2010; Flammer et al., 2012]. This relates to the
so-called diabetic angiogenic paradox [Costa, 2011]. Decreased
cEPCs were reported in diabetes challenged with: ischemia, wound
healing, coronary, and peripheral artery disease [Fadini et al., 2005;
Gallagher et al., 2007; De Falco et al., 2009; Antonio et al., 2014].
Whereas, EPCs increase was associated to diabetic retinopathy (DR),
characterized by excessive neovascularization [Fadini et al., 2006;
Liu et al., 2010]. However, deﬁcient vascular formation may co-exist
Fig. 3. Plasmatic quantiﬁcation of SDF-1a and testosterone. (A) Diabetic animals presented a signiﬁcant reduction in systemic SDF-1a and (B) testosterone. Insulin therapy
prevented the effects of diabetes, increasing SDF-1a and testosterone levels. Data presented as Mean SE.  P< 0.01, P< 0.001 diabetics compared to control group;
##P< 0.01 diabetic group compared to insulin-treated diabetics.
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with DR in the same subject, making it a paradigm. Our 8-week T1D
model, does not develop DR, and was not challenged with any
vascular trauma, which can explain the lack of difference in cEPCs
between groups. Additionally, to avoid the possible inﬂuence of
circadian regulation, we isolatedMNCs in all groups at the same hour
of the day [Thomas et al., 2008]. Nonetheless, our results do not
corroborate recent data in T1D ED patients, where a decrease in
peripheral EPCs was observed [Maiorino et al., 2015]. This study
enrolled long-term men with diabetes, and EPCs reduction could be
attributed to other vascular complications associated to the disease.
Our results, have however, shown that a CD34þCD133-VEGFR2þ
subpopulation was increased in diabetic PB. These may identify
putative CECs that have sloughed from vessels walls. In fact,
augmented CECs have been considered surrogate markers of severe
endothelium injury [Blann and Pretorius, 2006] and related to
systemic vascular disease associated to diabetes [Abraham et al.,
2004; Asicioglu et al., 2010]. This unbalance towards vascular
damage was successfully prevented by insulin therapy, suggesting a
protective role in ameliorating diabetic-related vascular complica-
tions. In support, one publication has showed that optimized
Fig. 4. Quantitative immunohistochemistry of SDF-1a experimental penile tissue. (A, B) SDF-1a protein expression levels as quantiﬁed in SDF-1a/DAB stained slides by
ImageJ color deconvolution, revealed a signiﬁcant decrease in SDF-1a in diabetic corpus cavernosum (CC), when compared with age-matched controls. Insulin therapy increased
SDF-1a protein to values in the range of controls. Data presented as Mean SE. P< 0.05, diabetics compared to control group; #P< 0.05 diabetic group compared to
insulin-treated diabetics. RGB, Red Green Blue; DAB, diaminobenzidine. (C) Co-localization of SDF-1a and a-smooth muscle actin (a-SMA) by dual immunolabeling
demonstrated that SDF-1a protein was predominantly present in perivascular smooth muscle cells (SMCs) in all groups analyzed. In certain vascular spaces SDF-1a was clearly
identiﬁed lining the sinosoids (upper panel; white arrow). DAPI, 40 ,6-diamidino-2-phenylindole (DNA intercalator). Bars, 100mm.
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glycemic control in patients with diabetes improved indexes of
endothelial damage, as assessed by CECs evaluation [Fadini et al.,
2011].
Next, we investigated the effect of insulin on EPCs modulators
SDF-1a and testosterone. We observed that insulin administra-
tion signiﬁcantly increased systemic SDF-1a, which was reduced
in diabetics. To our knowledge, SDF-1a plasma levels have not
been investigated in the same diabetic conditions as ours.
A single report has assessed plasmatic SDF-1a in STZ-induced
animals after being challenged with acute hind limb ischemia [De
Falco et al., 2009]. Another showed that circulating SDF-1a was
reduced in transgenic db/db mice [Chen et al., 2012]. To date
there are no studies referring the effects of insulin in SDF-1a
levels altered by diabetes. We hypothesized that normalized
glucose prevented diabetes metabolic alterations, rescuing
SDF-1a. Additionally, putative CECs decrease in treated-insulin
rats may also be related to SDF-1a increase. Mature ECs also
express CXCR4 and SDF-1a is thought to exert a direct action on
endothelial functions [Carr et al., 2006]. Further, it is known that
testosterone deﬁciency is a prevalent disorder associated to
diabetes [Tesone et al., 1980; Xu et al., 2014]. Concordantly, we
observed a reduction in testosterone levels in animals with
diabetes, which was rescued to control values by insulin. These
data are corroborated by previous research demonstrating a
reduction on plasma testosterone in diabetic models, which was
also restored to normal levels by insulin replacement therapy
[Tesone et al., 1980; Xu et al., 2014]. It was also shown that
androgens may play a role in EPCs modulation and EC function
[Foresta et al., 2008; Castela et al., 2011]. Although no alterations
in PB EPCs were observed after insulin treatment, the decrease in
endothelial damage may also be related to a testosterone
protective effect in vascular endothelium.
In addition to the regulatory role of systemic SDF-1a, we also
evaluated if insulin modulated this chemokine in CC. To the best of
our knowledge, this is the ﬁrst study evaluating SDF-1a in diabetic
cavernosal tissue. We observed a decrease in SDF-1a protein in both
diabetes experimental penile tissue and in human samples harvested
from men with diabetes [Costa et al., 2009; Angulo et al., 2010]. This
alteration was prevented in rat CC when treated with insulin. This
observation suggests a possible role for SDF-1a in penile vascular
homeostasis. Given more consistency to this result is the fact that
insulin administration prevented the effect of diabetes in SDF-1a
expression. We thus, hypothesized that SDF-1a may mediate
cavernosal endothelial homeostasis by binding to CXCR4 in
the endothelium [Carr et al., 2006]. The axis SDF-1a/CXCR4 may
be relevant for the maintenance of penile vascular function, most
Fig. 5. SDF-1a protein evaluation in human non-diabetic and diabetic cavernosal samples. (A, B) SDF-1a protein levels were quantiﬁed in SDF-1a/DAB stained corporeal
tissues using ImageJ color deconvolution. Quantitative immunohistochemistry showed a signiﬁcant reduction in SDF-1a protein expression in human diabetic erectile.
(C) Double immunoﬂuorescence for SDF-1a/a-SMA demonstrated positive labeling in cavernosal SMCs. Data presented as Mean SE. P< 0.01. RGB, Red Green Blue. DAB,
diaminobenzidine. DAPI, 40 ,6-diamidino-2-phenylindole (DNA intercalator). Bars, 100mm.
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likely mediating locally re-endothelialization mechanisms. In sum,
we demonstrated the beneﬁcial effects of insulin therapy in
preventing the noxious effects of diabetes in vascular function
associated with diabetic-ED. Glycemic control was able to promote
BM function, reducing levels of CECs, modulating systemic SDF-1a
and testosterone, and regulating penile SDF-1a protein expression.
We provided evidence of the relevance of early glycemic control
in preventing vascular-related alterations in diabetes. The improve-
ment in systemic and cavernosal endothelial health was attained by
the amelioration of vascular damage markers, and increase in
protective proteins and pathways. These ﬁndings highlight the
importance of insulin-induced normoglycemia in modulating
endothelial mediators and preventing EDys. Ongoing research will
unveil if EPCs have the ability to be recruited to injured diabetic
penile vasculature and functionally integrate cavernosal endothe-
lium, contributing to endogenous repair.
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